Cambios
En el instante 30 de mayo de 2024, 15:07:53 UTC,

-
Ningún campo fue actualizado. Compruebe la comparativa de metadatos para más detalles.
f | 1 | { | f | 1 | { |
2 | "author": null, | 2 | "author": null, | ||
3 | "author_email": null, | 3 | "author_email": null, | ||
4 | "conforms_to": [], | 4 | "conforms_to": [], | ||
5 | "coverage_new": {}, | 5 | "coverage_new": {}, | ||
6 | "creator_user_id": "196556b3-e0c4-4c51-a9e6-f51cc752bc37", | 6 | "creator_user_id": "196556b3-e0c4-4c51-a9e6-f51cc752bc37", | ||
7 | "description": { | 7 | "description": { | ||
8 | "en": "Non-rare thrombophilias (NRT) are hereditary | 8 | "en": "Non-rare thrombophilias (NRT) are hereditary | ||
9 | predispositions to thromboembolism, the most severe side-effect of | 9 | predispositions to thromboembolism, the most severe side-effect of | ||
10 | hormonal contraception. In the mid-1990s, the identification of NRT | 10 | hormonal contraception. In the mid-1990s, the identification of NRT | ||
11 | stirred up a controversy over the possibility of investigating these | 11 | stirred up a controversy over the possibility of investigating these | ||
12 | genetic variants in women wishing to use contraception. Appraising how | 12 | genetic variants in women wishing to use contraception. Appraising how | ||
13 | to handle this test led the medical profession to reconfigure the risk | 13 | to handle this test led the medical profession to reconfigure the risk | ||
14 | visibility on hormonal contraception. Through a review of scientific | 14 | visibility on hormonal contraception. Through a review of scientific | ||
15 | literature, this paper reconstructs the debate over whether and how | 15 | literature, this paper reconstructs the debate over whether and how | ||
16 | NRT genetic tests should enter the distribution system of | 16 | NRT genetic tests should enter the distribution system of | ||
17 | pharmacological contraception. The main arguments concern their | 17 | pharmacological contraception. The main arguments concern their | ||
18 | epidemiological, social, economic, and clinical consequences of these | 18 | epidemiological, social, economic, and clinical consequences of these | ||
19 | risk factors. We analyze this debate as a process consisting in | 19 | risk factors. We analyze this debate as a process consisting in | ||
20 | shaping the risk visibility. To those who opt for selective | 20 | shaping the risk visibility. To those who opt for selective | ||
21 | thrombophilia screening, this test should become a part of the medical | 21 | thrombophilia screening, this test should become a part of the medical | ||
22 | decision-making process, and its visibility should be kept under | 22 | decision-making process, and its visibility should be kept under | ||
23 | medical control to protect contraception safety. To advocates of | 23 | medical control to protect contraception safety. To advocates of | ||
24 | universal or \u201cextended\u201d screening, NRT visibility becomes a | 24 | universal or \u201cextended\u201d screening, NRT visibility becomes a | ||
25 | moral/legal obligation, and the test a valuable, if not mandatory, | 25 | moral/legal obligation, and the test a valuable, if not mandatory, | ||
26 | means to assure contraception safety. Risk visibility reveals | 26 | means to assure contraception safety. Risk visibility reveals | ||
27 | assumptions about medical power, women\u2019s responsibility, and drug | 27 | assumptions about medical power, women\u2019s responsibility, and drug | ||
28 | safety, and points to an appraisal process as an ideal field to | 28 | safety, and points to an appraisal process as an ideal field to | ||
29 | explore political and epistemological implications of screening.", | 29 | explore political and epistemological implications of screening.", | ||
30 | "es": "Non-rare thrombophilias (NRT) are hereditary | 30 | "es": "Non-rare thrombophilias (NRT) are hereditary | ||
31 | predispositions to thromboembolism, the most severe side-effect of | 31 | predispositions to thromboembolism, the most severe side-effect of | ||
32 | hormonal contraception. In the mid-1990s, the identification of NRT | 32 | hormonal contraception. In the mid-1990s, the identification of NRT | ||
33 | stirred up a controversy over the possibility of investigating these | 33 | stirred up a controversy over the possibility of investigating these | ||
34 | genetic variants in women wishing to use contraception. Appraising how | 34 | genetic variants in women wishing to use contraception. Appraising how | ||
35 | to handle this test led the medical profession to reconfigure the risk | 35 | to handle this test led the medical profession to reconfigure the risk | ||
36 | visibility on hormonal contraception. Through a review of scientific | 36 | visibility on hormonal contraception. Through a review of scientific | ||
37 | literature, this paper reconstructs the debate over whether and how | 37 | literature, this paper reconstructs the debate over whether and how | ||
38 | NRT genetic tests should enter the distribution system of | 38 | NRT genetic tests should enter the distribution system of | ||
39 | pharmacological contraception. The main arguments concern their | 39 | pharmacological contraception. The main arguments concern their | ||
40 | epidemiological, social, economic, and clinical consequences of these | 40 | epidemiological, social, economic, and clinical consequences of these | ||
41 | risk factors. We analyze this debate as a process consisting in | 41 | risk factors. We analyze this debate as a process consisting in | ||
42 | shaping the risk visibility. To those who opt for selective | 42 | shaping the risk visibility. To those who opt for selective | ||
43 | thrombophilia screening, this test should become a part of the medical | 43 | thrombophilia screening, this test should become a part of the medical | ||
44 | decision-making process, and its visibility should be kept under | 44 | decision-making process, and its visibility should be kept under | ||
45 | medical control to protect contraception safety. To advocates of | 45 | medical control to protect contraception safety. To advocates of | ||
46 | universal or \u201cextended\u201d screening, NRT visibility becomes a | 46 | universal or \u201cextended\u201d screening, NRT visibility becomes a | ||
47 | moral/legal obligation, and the test a valuable, if not mandatory, | 47 | moral/legal obligation, and the test a valuable, if not mandatory, | ||
48 | means to assure contraception safety. Risk visibility reveals | 48 | means to assure contraception safety. Risk visibility reveals | ||
49 | assumptions about medical power, women\u2019s responsibility, and drug | 49 | assumptions about medical power, women\u2019s responsibility, and drug | ||
50 | safety, and points to an appraisal process as an ideal field to | 50 | safety, and points to an appraisal process as an ideal field to | ||
51 | explore political and epistemological implications of screening." | 51 | explore political and epistemological implications of screening." | ||
52 | }, | 52 | }, | ||
53 | "groups": [], | 53 | "groups": [], | ||
54 | "id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | 54 | "id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | ||
55 | "identifier": "https://doi.org/10.20350/digitalCSIC/13972", | 55 | "identifier": "https://doi.org/10.20350/digitalCSIC/13972", | ||
56 | "isopen": false, | 56 | "isopen": false, | ||
57 | "issued_date": "2021-08-11T00:00:00", | 57 | "issued_date": "2021-08-11T00:00:00", | ||
58 | "language": [ | 58 | "language": [ | ||
59 | "en" | 59 | "en" | ||
60 | ], | 60 | ], | ||
61 | "license_id": "https://creativecommons.org/licenses/by/4.0/", | 61 | "license_id": "https://creativecommons.org/licenses/by/4.0/", | ||
62 | "license_title": "https://creativecommons.org/licenses/by/4.0/", | 62 | "license_title": "https://creativecommons.org/licenses/by/4.0/", | ||
63 | "maintainer": null, | 63 | "maintainer": null, | ||
64 | "maintainer_email": null, | 64 | "maintainer_email": null, | ||
65 | "metadata_created": "2024-05-30T15:07:18.449422", | 65 | "metadata_created": "2024-05-30T15:07:18.449422", | ||
n | 66 | "metadata_modified": "2024-05-30T15:07:53.013564", | n | 66 | "metadata_modified": "2024-05-30T15:07:53.128911", |
67 | "multilingual_tags": { | 67 | "multilingual_tags": { | ||
68 | "en": [ | 68 | "en": [ | ||
69 | "Visibility", | 69 | "Visibility", | ||
70 | "Risk", | 70 | "Risk", | ||
71 | "Screening", | 71 | "Screening", | ||
72 | "Controversy", | 72 | "Controversy", | ||
73 | "Hormonal contraception", | 73 | "Hormonal contraception", | ||
74 | "Medical profession role", | 74 | "Medical profession role", | ||
75 | "Adverse drug reactions" | 75 | "Adverse drug reactions" | ||
76 | ], | 76 | ], | ||
77 | "es": [ | 77 | "es": [ | ||
78 | "\u00c9tica m\u00e9dica", | 78 | "\u00c9tica m\u00e9dica", | ||
79 | "Salud de la mujer", | 79 | "Salud de la mujer", | ||
80 | "Visibility", | 80 | "Visibility", | ||
81 | "Risk", | 81 | "Risk", | ||
82 | "Screening", | 82 | "Screening", | ||
83 | "Controversy", | 83 | "Controversy", | ||
84 | "Hormonal contraception", | 84 | "Hormonal contraception", | ||
85 | "Medical profession role", | 85 | "Medical profession role", | ||
86 | "Adverse drug reactions" | 86 | "Adverse drug reactions" | ||
87 | ] | 87 | ] | ||
88 | }, | 88 | }, | ||
89 | "name": | 89 | "name": | ||
90 | -risk-in-visible-the-medical-debate-over-non-rare-thrombophilia-nrt-", | 90 | -risk-in-visible-the-medical-debate-over-non-rare-thrombophilia-nrt-", | ||
91 | "notes": null, | 91 | "notes": null, | ||
92 | "num_resources": 2, | 92 | "num_resources": 2, | ||
93 | "num_tags": 0, | 93 | "num_tags": 0, | ||
94 | "organization": { | 94 | "organization": { | ||
95 | "approval_status": "approved", | 95 | "approval_status": "approved", | ||
96 | "created": "2023-09-25T13:00:48.436872", | 96 | "created": "2023-09-25T13:00:48.436872", | ||
97 | "description": "El Instituto de Pol\u00edticas y Bienes | 97 | "description": "El Instituto de Pol\u00edticas y Bienes | ||
98 | P\u00fablicos (IPP) es un instituto del CSIC que se cre\u00f3 en 2007, | 98 | P\u00fablicos (IPP) es un instituto del CSIC que se cre\u00f3 en 2007, | ||
99 | con el objetivo de generar investigaci\u00f3n cient\u00edfica de | 99 | con el objetivo de generar investigaci\u00f3n cient\u00edfica de | ||
100 | excelencia internacional y de gran impacto social en el \u00e1mbito | 100 | excelencia internacional y de gran impacto social en el \u00e1mbito | ||
101 | del an\u00e1lisis de las pol\u00edticas p\u00fablicas. \r\n\r\nEl IPP | 101 | del an\u00e1lisis de las pol\u00edticas p\u00fablicas. \r\n\r\nEl IPP | ||
102 | tiene como misi\u00f3n la generaci\u00f3n de conocimiento | 102 | tiene como misi\u00f3n la generaci\u00f3n de conocimiento | ||
103 | cient\u00edfico en torno al an\u00e1lisis de pol\u00edticas y bienes | 103 | cient\u00edfico en torno al an\u00e1lisis de pol\u00edticas y bienes | ||
104 | p\u00fablicos, as\u00ed como su gesti\u00f3n por medio de | 104 | p\u00fablicos, as\u00ed como su gesti\u00f3n por medio de | ||
105 | organizaciones privadas, instituciones p\u00fablicas y otros actores | 105 | organizaciones privadas, instituciones p\u00fablicas y otros actores | ||
106 | sociales.", | 106 | sociales.", | ||
107 | "id": "7ee09a95-0735-4848-8c8a-c17381c4278a", | 107 | "id": "7ee09a95-0735-4848-8c8a-c17381c4278a", | ||
108 | "image_url": "2023-09-25-110048.431222ipp0.png", | 108 | "image_url": "2023-09-25-110048.431222ipp0.png", | ||
109 | "is_organization": true, | 109 | "is_organization": true, | ||
110 | "name": "instituto-de-politicas-y-bienes-publicos-ipp-csic", | 110 | "name": "instituto-de-politicas-y-bienes-publicos-ipp-csic", | ||
111 | "state": "active", | 111 | "state": "active", | ||
112 | "title": "Instituto de Pol\u00edticas y Bienes P\u00fablicos | 112 | "title": "Instituto de Pol\u00edticas y Bienes P\u00fablicos | ||
113 | (IPP), CSIC", | 113 | (IPP), CSIC", | ||
114 | "type": "organization" | 114 | "type": "organization" | ||
115 | }, | 115 | }, | ||
116 | "owner_org": "7ee09a95-0735-4848-8c8a-c17381c4278a", | 116 | "owner_org": "7ee09a95-0735-4848-8c8a-c17381c4278a", | ||
117 | "private": false, | 117 | "private": false, | ||
118 | "publisher": "7ee09a95-0735-4848-8c8a-c17381c4278a", | 118 | "publisher": "7ee09a95-0735-4848-8c8a-c17381c4278a", | ||
119 | "reference": [ | 119 | "reference": [ | ||
120 | "http://vocabularies.unesco.org/thesaurus/concept1014", | 120 | "http://vocabularies.unesco.org/thesaurus/concept1014", | ||
121 | "http://vocabularies.unesco.org/thesaurus/concept11771" | 121 | "http://vocabularies.unesco.org/thesaurus/concept11771" | ||
122 | ], | 122 | ], | ||
123 | "relationships_as_object": [], | 123 | "relationships_as_object": [], | ||
124 | "relationships_as_subject": [], | 124 | "relationships_as_subject": [], | ||
125 | "resources": [ | 125 | "resources": [ | ||
126 | { | 126 | { | ||
127 | "byte_size": "762,68 kB", | 127 | "byte_size": "762,68 kB", | ||
128 | "cache_last_updated": null, | 128 | "cache_last_updated": null, | ||
129 | "cache_url": null, | 129 | "cache_url": null, | ||
130 | "created": "2024-05-30T15:07:39.741677", | 130 | "created": "2024-05-30T15:07:39.741677", | ||
131 | "datastore_active": false, | 131 | "datastore_active": false, | ||
132 | "description": null, | 132 | "description": null, | ||
133 | "format": "pdf", | 133 | "format": "pdf", | ||
134 | "hash": "", | 134 | "hash": "", | ||
135 | "id": "64984dde-89cf-45f4-b74b-667fb64f01c9", | 135 | "id": "64984dde-89cf-45f4-b74b-667fb64f01c9", | ||
136 | "last_modified": null, | 136 | "last_modified": null, | ||
137 | "metadata_modified": "2024-05-30T15:07:53.015646", | 137 | "metadata_modified": "2024-05-30T15:07:53.015646", | ||
138 | "mimetype": "application/pdf", | 138 | "mimetype": "application/pdf", | ||
139 | "mimetype_inner": null, | 139 | "mimetype_inner": null, | ||
140 | "name": | 140 | "name": | ||
141 | "Appraising_screening_making_risk_in-visible_dataset.pdf", | 141 | "Appraising_screening_making_risk_in-visible_dataset.pdf", | ||
142 | "name_translated": { | 142 | "name_translated": { | ||
143 | "en": | 143 | "en": | ||
144 | "Appraising_screening_making_risk_in-visible_dataset.pdf", | 144 | "Appraising_screening_making_risk_in-visible_dataset.pdf", | ||
145 | "es": | 145 | "es": | ||
146 | "Appraising_screening_making_risk_in-visible_dataset.pdf" | 146 | "Appraising_screening_making_risk_in-visible_dataset.pdf" | ||
147 | }, | 147 | }, | ||
148 | "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | 148 | "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | ||
149 | "position": 0, | 149 | "position": 0, | ||
150 | "resource_identifier": "", | 150 | "resource_identifier": "", | ||
151 | "resource_relation": [], | 151 | "resource_relation": [], | ||
152 | "resource_relation-1": "", | 152 | "resource_relation-1": "", | ||
153 | "resource_type": null, | 153 | "resource_type": null, | ||
154 | "size": null, | 154 | "size": null, | ||
155 | "state": "active", | 155 | "state": "active", | ||
156 | "url": | 156 | "url": | ||
157 | 261/247857/1/Appraising_screening_making_risk_in-visible_dataset.pdf", | 157 | 261/247857/1/Appraising_screening_making_risk_in-visible_dataset.pdf", | ||
158 | "url_type": null | 158 | "url_type": null | ||
159 | }, | 159 | }, | ||
160 | { | 160 | { | ||
161 | "byte_size": "2,93 kB", | 161 | "byte_size": "2,93 kB", | ||
162 | "cache_last_updated": null, | 162 | "cache_last_updated": null, | ||
163 | "cache_url": null, | 163 | "cache_url": null, | ||
164 | "created": "2024-05-30T15:07:53.017722", | 164 | "created": "2024-05-30T15:07:53.017722", | ||
165 | "datastore_active": false, | 165 | "datastore_active": false, | ||
166 | "description": null, | 166 | "description": null, | ||
167 | "format": "txt", | 167 | "format": "txt", | ||
168 | "hash": "", | 168 | "hash": "", | ||
169 | "id": "1eac16de-d790-4bec-ac0a-da4c5b740d37", | 169 | "id": "1eac16de-d790-4bec-ac0a-da4c5b740d37", | ||
170 | "last_modified": null, | 170 | "last_modified": null, | ||
n | 171 | "metadata_modified": "2024-05-30T15:07:53.015781", | n | 171 | "metadata_modified": "2024-05-30T15:07:53.131162", |
172 | "mimetype": "text/plain", | 172 | "mimetype": "text/plain", | ||
173 | "mimetype_inner": null, | 173 | "mimetype_inner": null, | ||
174 | "name": "Appraising_screening_DATASET.txt", | 174 | "name": "Appraising_screening_DATASET.txt", | ||
175 | "name_translated": { | 175 | "name_translated": { | ||
176 | "en": "Appraising_screening_DATASET.txt", | 176 | "en": "Appraising_screening_DATASET.txt", | ||
177 | "es": "Appraising_screening_DATASET.txt" | 177 | "es": "Appraising_screening_DATASET.txt" | ||
178 | }, | 178 | }, | ||
179 | "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | 179 | "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24", | ||
180 | "position": 1, | 180 | "position": 1, | ||
181 | "resource_identifier": "", | 181 | "resource_identifier": "", | ||
182 | "resource_relation": [], | 182 | "resource_relation": [], | ||
183 | "resource_relation-1": "", | 183 | "resource_relation-1": "", | ||
184 | "resource_type": null, | 184 | "resource_type": null, | ||
185 | "size": null, | 185 | "size": null, | ||
186 | "state": "active", | 186 | "state": "active", | ||
187 | "url": | 187 | "url": | ||
188 | al.csic.es/bitstream/10261/247857/4/Appraising_screening_DATASET.txt", | 188 | al.csic.es/bitstream/10261/247857/4/Appraising_screening_DATASET.txt", | ||
189 | "url_type": null | 189 | "url_type": null | ||
190 | } | 190 | } | ||
191 | ], | 191 | ], | ||
192 | "spatial": [], | 192 | "spatial": [], | ||
t | 193 | "state": "draft", | t | 193 | "state": "active", |
194 | "tags": [], | 194 | "tags": [], | ||
195 | "theme": [ | 195 | "theme": [ | ||
196 | 196 | ||||
197 | "http://datos.gob.es/kos/sector-publico/sector/ciencia-tecnologia", | 197 | "http://datos.gob.es/kos/sector-publico/sector/ciencia-tecnologia", | ||
198 | "http://datos.gob.es/kos/sector-publico/sector/cultura-ocio", | 198 | "http://datos.gob.es/kos/sector-publico/sector/cultura-ocio", | ||
199 | "http://datos.gob.es/kos/sector-publico/sector/educacion", | 199 | "http://datos.gob.es/kos/sector-publico/sector/educacion", | ||
200 | "http://datos.gob.es/kos/sector-publico/sector/salud", | 200 | "http://datos.gob.es/kos/sector-publico/sector/salud", | ||
201 | "http://datos.gob.es/kos/sector-publico/sector/sector-publico" | 201 | "http://datos.gob.es/kos/sector-publico/sector/sector-publico" | ||
202 | ], | 202 | ], | ||
203 | "title": "Appraising screening, making risk in/visible. The medical | 203 | "title": "Appraising screening, making risk in/visible. The medical | ||
204 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | 204 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | ||
205 | the pill", | 205 | the pill", | ||
206 | "title_translated": { | 206 | "title_translated": { | ||
207 | "en": "Appraising screening, making risk in/visible. The medical | 207 | "en": "Appraising screening, making risk in/visible. The medical | ||
208 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | 208 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | ||
209 | the pill", | 209 | the pill", | ||
210 | "es": "Appraising screening, making risk in/visible. The medical | 210 | "es": "Appraising screening, making risk in/visible. The medical | ||
211 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | 211 | debate over Non-Rare Thrombophilia (NRT) testing before prescribing | ||
212 | the pill" | 212 | the pill" | ||
213 | }, | 213 | }, | ||
214 | "type": "dataset", | 214 | "type": "dataset", | ||
215 | "url": null, | 215 | "url": null, | ||
216 | "version": null | 216 | "version": null | ||
217 | } | 217 | } |